GBA1 and Parkinson disease: The molecular diagnosis of mutation at the GBA1 DNA level is a prerequisite for the diagnosis; hence, having the eponym would facilitate genetic testing at large for all newly diagnosed patients with PD, thereby serving the best interest of the PD population beyond GBA1.